Related Experiment Video
Updated: Mar 24, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Allosteric Modulation of the Calcium-sensing Receptor Rectifies Signaling Abnormalities Associated with G-protein
Valerie N Babinsky1, Fadil M Hannan2, Caroline M Gorvin1
1From the Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LJ, United Kingdom.
Abstract:
Germline loss- and gain-of-function mutations of G-protein α-11 (Gα11), which couples the calcium-sensing receptor (CaSR) to intracellular calcium (Ca(2+) i) signaling, lead to familial hypocalciuric hypercalcemia type 2 (FHH2) and autosomal dominant hypocalcemia type 2 (ADH2), respectively, whereas somatic Gα11 mutations mediate uveal melanoma development by constitutively up-regulating MAPK signaling. Cinacalcet and NPS-2143 are allosteric CaSR activators and inactivators, respectively, that ameliorate signaling disturbances associated with CaSR mutations, but their potential to modulate abnormalities of the downstream Gα11 protein is unknown. This study investigated whether cinacalcet and NPS-2143 may rectify Ca(2+) i alterations associated with FHH2- and ADH2-causing Gα11 mutations, and evaluated the influence of germline gain-of-function Gα11 mutations on MAPK signaling by measuring ERK phosphorylation, and assessed the effect of NPS-2143 on a uveal melanoma Gα11 mutant. WT and mutant Gα11 proteins causing FHH2, ADH2 or uveal melanoma were transfected in CaSR-expressing HEK293 cells, and Ca(2+) i and ERK phosphorylation responses measured by flow-cytometry and Alphascreen immunoassay following exposure to extracellular Ca(2+) (Ca(2+) o) and allosteric modulators. Cinacalcet and NPS-2143 rectified the Ca(2+) i responses of FHH2- and ADH2-associated Gα11 loss- and gain-of-function mutations, respectively. ADH2-causing Gα11 mutations were demonstrated not to be constitutively activating and induced ERK phosphorylation following Ca(2+) o stimulation only. The increased ERK phosphorylation associated with ADH2 and uveal melanoma mutants was rectified by NPS-2143. These findings demonstrate that CaSR-targeted compounds can rectify signaling disturbances caused by germline and somatic Gα11 mutations, which respectively lead to calcium disorders and tumorigenesis; and that ADH2-causing Gα11 mutations induce non-constitutive alterations in MAPK signaling.
Insights
This study shows that CaSR-targeted drugs can correct signaling issues in Gα11 mutations linked to calcium disorders and uveal melanoma. These compounds effectively normalize intracellular calcium levels and MAPK signaling in affected cells.
Area of Science:
- Biochemistry
- Molecular Biology
- Genetics
Background:
- Germline Gα11 mutations cause familial hypocalciuric hypercalcemia type 2 (FHH2) and autosomal dominant hypocalcemia type 2 (ADH2).
- Somatic Gα11 mutations are implicated in uveal melanoma development through MAPK signaling.
- Allosteric CaSR modulators (cinacalcet, NPS-2143) affect CaSR signaling but their impact on downstream Gα11 is unclear.
Purpose of the Study:
- Investigate if cinacalcet and NPS-2143 can correct intracellular calcium (Ca(2+)i) alterations in FHH2 and ADH2.
- Evaluate the effect of Gα11 mutations on MAPK signaling (ERK phosphorylation).
- Assess NPS-2143's efficacy on a uveal melanoma Gα11 mutant.
Main Methods:
- Transfection of wild-type (WT) and mutant Gα11 proteins (FHH2, ADH2, uveal melanoma) into HEK293 cells expressing CaSR.
- Measurement of Ca(2+)i and ERK phosphorylation using flow cytometry and Alphascreen immunoassay.
- Exposure to extracellular calcium (Ca(2+)o) and allosteric modulators.
Main Results:
- Cinacalcet and NPS-2143 corrected Ca(2+)i responses in FHH2 and ADH2 Gα11 mutants.
- ADH2-associated Gα11 mutations did not show constitutive activation, inducing ERK phosphorylation only upon Ca(2+)o stimulation.
- NPS-2143 rectified increased ERK phosphorylation in ADH2 and uveal melanoma Gα11 mutants.
Conclusions:
- CaSR-targeted compounds can rectify signaling disturbances from germline and somatic Gα11 mutations.
- These compounds show potential for treating calcium disorders and uveal melanoma.
- ADH2-causing Gα11 mutations involve non-constitutive alterations in MAPK signaling.
Related Concept Videos
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Activation and Inactivation of G Proteins
G-Protein Gated Ion Channels
Sensory...
GPCRs Regulate Adenylyl Cylase Activity
GPCR Desensitization
Amplifying Signals via Enzymatic Cascade

